Modality
Degrader
MOA
PCSK9i
Target
CFTR
Pathway
STING
LGSParkinson'sMCL
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
Apr 2019
→ Jun 2029
Phase 2Current
NCT03075619
2,882 pts·MCL
2019-04→2029-06·Active
2,882 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-283.2y awayPh2 Data· MCL
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Active
Catalysts
Ph2 Data
2029-06-28 · 3.2y away
MCL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03075619 | Phase 2 | MCL | Active | 2882 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Sovarelsin | BioMarin | Phase 2 | CFTR |